Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor

Hippocampus

Volumn 23, Issue 10, 2013, Pages 942-951

  Moriguchi, Shigeki ^a,b   Tanaka, Tomoya ^a   Narahashi, Toshio ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcium calmodulin dependent protein kinase II; Glycine binding site of NMDAR; Long term potentiation; Protein kinase C ; Sunifiram

Indexed keywords

7 CHLOROKYNURENIC ACID; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GLYCINE; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOOTROPIC AGENT; PROTEIN KINASE C ALPHA; SUNIFIRAM; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; DM 235; KYNURENIC ACID; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; POLYAMINE; PROTEIN BINDING;

ADULT ANIMAL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; IMMUNOBLOTTING; LONG TERM POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNAPTIC EFFICACY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; ELECTRODE IMPLANT; METABOLISM; PHYSIOLOGY; SURGERY; SYNAPTIC TRANSMISSION;

ANIMALS; CA1 REGION, HIPPOCAMPAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; KYNURENIC ACID; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; NOOTROPIC AGENTS; PIPERAZINES; PIPERIDINES; POLYAMINES; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84884720641     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.22150     Document Type: Article

References (57)

1. Amadio M, Govoni S, Alkon DL, Pascale A. 2004. Emerging targets for the pharmacology of learning and memory. Pharmacol Res 50:111-122.
2. Barten DM, Albright CF. 2008. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 37:171-186.
3. Barria A, Muller D, Derkach V, Griffith LC, Soderling TR. 1997. Regulatory phosphorylation of AMPA-type glutamate receptor by CaM-KII during long-term potentiation. Science 276:2042-2045.
4. Baxter MG, Lanthorn TH, Frink KM, Golski S, Wan R, Olton DS. 1994. d-Cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol Aging 15:207-213.
5. Ben-Ari Y, Aniksztejn L, Bregestovski P. 1992. Protein kinase C modulation of NMDA currents: An important link for LTP induction. Trends Neurosci 15:333-339.
6. Bowie CR, Harvey PD. 2006. Treatment of cognitive deficits in schizophrenia. Curr Opin Investig Drugs 7:608-613.
7. Collingridge GL, Issac JT, Wang YT. 2004. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 5:952-962.
8. Cull-Candy S, Brickley S, Farrant M. 2001. NMDA receptor subunits: Diversity, development and disease. Curr Opin Neurobiol 11:327-335.
9. Della Rocca GJ, van Biesen T, Luttrell DK, Luttrell LM, Lefkowitz RJ. 1997. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 272:19125-19132.
10. Derkach V, Barria A, Soderling T. 1999. Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96:3269-3274.
11. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger JA. 1996. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383:547-550.
12. Dysken MW, Mendels J, LeWitt P. 1992. Milacemide; a placebo-controlled study in senile dementia of the Alzheimer type. Am J Geriatric psychiatry 40:503-506.
13. Fukunaga K, Sodering TR, Miyamoto E. 1992. Activation of Ca2+/calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J Biol Chem 267:22527-22533.
14. Fukunaga K, Stoppini L, Miyamoto E, Muller D. 1993. Long-term potentiation is associated with a increased activity of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem 268:7863-7867.
15. Fukunaga K, Muller D, Miyamoto E. 1995. Increased phosphorylation of Ca2+/calmodulin-dependent protein kinase II and its endogeneous substrates in the induction of long term potentiation. J Biol Chem 270:6119-6124.
16. Fukunaga K, Horikawa K, Shibata S, Takeuchi Y, Miyamoto E. 2002. Ca2+/calmodulin-dependent protein kinase II-dependent long-term potentiation in the rat suprachiasmatic nucleus and its inhibition by melatonin. J Neurosci Res 70:799-807.
17. Galeotti N, Ghelardini C, Pittaluga A, Pugliese AM, Bartolini A, Manetti D, Romanelli MN, Gualtieri F. 2003. AMPA-receptor activation is involved in the antiamnesic effect of DM232 (unifiram) and DM235 (sunifiram). Naunyn-Schmiedeberg's Arch Pharmacol 368:538-545.
18. Ghelardini C, Galeotti N, Gualtieri F, Romanelli MN, Bucherelli C, Baldi E, Bartolini A. 2002. DM235 (sunifiram): A novel nootropic with potential as a cognitive enhancer. Naunyn-Schmiedeberg's Arch Pharmacol 365:419-426.
19. Giacobini E. 2000. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's Disease. Alzheimer Dis Assoc Disorders 14 (Suppl 1):S3-S10.
20. Greenamyre JT, Penney JB, D'Amato CJ, Young AB. 1987. Dementia of the Alzheimer's type: Changes in hippocampal L-[3H]glutamate binding. J Neurochem 48:543-551.
21. Hanndelmann GE, Nevins ME, Mueller LL, Arnolde SM, Cordi AA. 1989. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav 34:823-828.
22. Ito I, Tanabe S, Kohda A, Sugiyama H. 1990. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 424:533-543.
23. Kelso S, Nelson TE, Leonard JP. 1992. Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes. J Physiol 449:705-718.
24. Kleckner NW, Dingledine R. 1998. Requirement of glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835-837.
25. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
26. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, Schlessinger J. 1995. Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions. Nature 376:737-745.
27. Li M, Yu W, Chen CH, Cwirla S, Whitehorn E, Tate E, Raab R, Bremer M, Dower B. 1996. In vitro selection of peptides acting at a new site of NMDA glutamate receptors. Nat Biotechnol 14:986-991.
28. Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330:613-622.
29. Lisman J, Schulman H, Cline H. 2002. The molecular basis of CaMKII function in synaptic and behavioral memory. Nat Rev Neurosci 3:175-190.
30. Lu YM, Roder JC, Davidow J, Salter MW. 1998. Src activation in the induction of long-term potentiation in CA1 hippocampal neurons. Science 279:1363-1367.
31. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. 1996. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 271:19443-19450.
32. Manetti D, Ghelardini C, Bartolini A, Bellucci C, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Scapecchi S, Teodori E. 2000. Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of high potent nootropic agents. J Med Chem 43:1969-1974.
33. Martini E, Salvicchi A, Ghelardini C, Manetti D, Dei S, Guandalini L, Martelli C, Melchiorre M, Cellai C, Scapecchi S, Teodori E, Romanelli MN. 2009. Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognitive-enhancers. Bioorg Med Chem 17:7606-7614.
34. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. 2003. Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther 307:160-167.
35. Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T. 2007. Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol 71:580-587.
36. Moriguchi S, Shioda N, Han F, Narahashi T, Fukunaga K. 2008. CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region. J Neurochem 106:1092-1103.
37. Moriguchi S, Han F, Shioda N, Yamamoto Y, Nakajima T, Nakagawasai O, Tadano T, Yeh JZ, Narahashi T, Fukunaga K. 2009. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice. J Neurochem 110:170-181.
38. Nakazawa T, Kojima S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T. 2001. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluRe{open}2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem 276:693-699.
39. Poncer JC, Esteban JA, Malinow R. 2002. Multiple mechanisms for the potentiation of AMPA receptor-mediated transmission by alpha-Ca2+/calmodulin-dependent protein kinase II. J Neurosci 22:4406-4411.
40. Rock DM, Macdonald RL. 1995. Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 35:463-482.
41. Rogers JM, Panegyres PK. 2007. Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations. J Clin Neurosci 14:919-927.
42. Scatena R, Martorana GE, Bottoni P, Botta G, Pastore P, Giardina B. 2007. An update on pharmacological approaches to neurodegenerative diseases. Expert Opin Investig Drugs 16:59-72.
43. Schwartz BL, Hashtroudi S, Herting RL, Handerson H, Deutsch SI. 1991. Glycine prodrug facilitates memory retrieval in humans. Neurology 41:1341-1343.
44. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. 1996. d-cycloserine enhances implicit memory in Alzheimer's patients. Neurology 46:420-424.
45. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R. 1999. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Sceince 284:1811-1816.
46. Sieber FE, Traystman RJ, Brown PR, Martin LJ. 1998. Protein kinase C expression and activity after global incomplete cerebral ischemia in dogs. Stroke 29:1445-1452.
47. Soderling TR, Derkach VA. 2000. Postsynaptic protein phosphorylation and LTP. Trends Neurosci 23:75-80.
48. Song I, Huganir RL. 2002. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci 25:578-588.
49. Tingley WG, Rocke KW, Thompson AK, Huganir RL. 1993. Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364:70-73.
50. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, Huganir RL. 1997. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 272:5157-5166.
51. Wafford KA, Kathoria M, Bain CJ, Marshall G, Le Bourdelles B, Kemp JA, Whiting PJ. 1995. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine-binding site. Mol Pharmacol 47:374-380.
52. Wilens TE, Decker MW. 2007. Neuronal nicotinic receptor agonist for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition. Biochem Pharmacol 74:1212-1223.
53. Xia Z, Storm DR. 2005. The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6:267-276.
54. Xiong ZG Raouf R, Lu WY, Wang LY, Orser BA, Dudek EM, Browning MD, MacDonald JF. 1998. Regulation of N-methyl-D-aspartate receptor function by constitutively active protein kinase C. Mol Pharmacol 54:1055-1063.
55. Yoshii M, Watabe S, Sakurai T, Shiotani T. 1997. Cellular mechanism of underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav Brain Res 83:185-188.
56. Zhao X, Kuryatov A, Lindstorm JM, Yeh JZ, Narahashi T. 2001. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol Pharmacol 59:674-683.
57. Zukin RS, Bennett MV. 1995. Alternatively spiced isoforms of the NMDARI receptor subunit. Trend Neurosci 18:306-313.